Consort Medical said that Bespak has entered into a master development agreement including key commercial supply terms with a leading global biopharmaceutical company.
The agreement is focused on Bespak's novel Vapoursoft driven auto-injector technology, Syrina.
Under the agreement, Bespak will develop a Syrina embodiment of a single product through to commercialisation.
The framework of the agreement also allows for inclusion of additional development programmes for other products.
In the event that the Company elects to commercialise the developed device, the agreement provides that the parties will enter into a full commercial supply agreement.
Syrina is one of a range of novel technologies developed at Bespak's Cambridge, UK based Innovation Centre.
Through the use of a liquid gas propellant, rather than a spring to drive the delivery of the drug, Syrina facilitates delivery of a broader range of drug formulations and volumes, whilst also reducing or eliminating potential for glass syringe breakage.